Top

Current Cardiovascular Imaging Reports

Published in:

Open Access 26-09-2023 | Positron Emission Tomography | Review

⁶⁸Ga-FAPi: Pathways and Diagnosis in Cardiac Imaging

Authors: Cristina Elena Popescu, Paola Ferro, Irene Gotuzzo, Irene Burger, Axel Rominger, Federico Caobelli

Published in: Current Cardiovascular Imaging Reports | Issue 11/2023

Abstract

Purpose of Review

Myocardial fibrosis is a response to myocardial injury and plays a pivotal role in ventricular remodeling. Different patterns of fibrosis are associated with different disease states, but the presence and amount of fibrosis provide a different impact on prognosis.

Recent Findings

In the latest years, fibroblast activation protein inhibitor (FAPi) positron emission tomography (PET) gain interest for its potential in detecting myocardial fibrosis, in differentiating between active and chronic disease, and in the assessment of disease progression and response to treatment.

Summary

We aim to highlight the most relevant current applications of FAPi PET/CT in cardiovascular imaging, focusing on its applications, advantages, limitations, and to underline future clinical perspective.

Hamson EJ, Keane FM, Tholen S, Schilling O, Gorrell MD. Understanding fibroblast activation protein (FAP): substrates, activities, expression and targeting for cancer therapy. Proteomics Clin Appl. 2014;8(5–6):454–63. https://doi.org/10.1002/prca.201300095.CrossRefPubMed

Brilla CG. Renin-angiotensin-aldosterone system and myocardial fibrosis. Cardiovasc Res. 2000;47(1):1–3. https://doi.org/10.1016/s0008-6363(00)00092-4.CrossRefPubMed

3.•

Sidrak MMA, De Feo MS, Corica F, Gorica J, Conte M, Filippi L, et al. Fibroblast activation protein inhibitor (FAPI)-based theranostics-where we are at and where we are heading: a systematic review. Int J Mol Sci. 2023;24(4):3863. https://doi.org/10.3390/ijms24043863. This is a recent Review paper on the theranostic potential of FAPI imaging.CrossRefPubMedPubMedCentral

Chen X, Song E. Turning foes to friends: targeting cancer-associated fibroblasts. Nat Rev Drug Discov. 2019;18(2):99–115. https://doi.org/10.1038/s41573-018-0004-1.CrossRefPubMed

Cheng JD, Dunbrack RL, Valianou M, Rogatko A, Alpaugh RK, Weiner LM. Promotion of tumor growth by murine fibroblast activation protein, a serine protease, in an animal model. Cancer Res. 2002;62(16):4767–72.PubMed

Santos AM, Jung J, Aziz N, Kissil JL, Puré E. Targeting fibroblast activation protein inhibits tumor stromagenesis and growth in mice. J Clin Invest. 2009;119(12):3613–25. https://doi.org/10.1172/JCI38988.CrossRefPubMedPubMedCentral

Siebermair J, Köhler MI, Kupusovic J, Nekolla SG, Kessler L, Ferdinandus J, et al. Cardiac fibroblast activation detected by Ga-68 FAPI PET imaging as a potential novel biomarker of cardiac injury/remodeling. J Nucl Cardiol. 2021;28(3):812–21. https://doi.org/10.1007/s12350-020-02307-w.CrossRefPubMed

Iking J, Staniszewska M, Kessler L, Klose JM, Lückerath K, Fendler WP, et al. Imaging inflammation with positron emission tomography. Biomedicines. 2021;9(2):212. https://doi.org/10.3390/biomedicines9020212.CrossRefPubMedPubMedCentral

Bengel FM, Ross TL. Emerging imaging targets for infiltrative cardiomyopathy: inflammation and fibrosis. J Nucl Cardiol. 2019;26(1):208–16. https://doi.org/10.1007/s12350-018-1356-y.CrossRefPubMed

10.

Prabhu SD, Frangogiannis NG. The Biological Basis for Cardiac Repair After Myocardial Infarction: From Inflammation to Fibrosis. Circ Res. 2016;119(1):91–112. https://doi.org/10.1161/CIRCRESAHA.116.303577.CrossRefPubMedPubMedCentral

11.

Kain V, Prabhu SD, Halade GV. Inflammation revisited: inflammation versus resolution of inflammation following myocardial infarction. Basic Res Cardiol. 2014;109(6):444. https://doi.org/10.1007/s00395-014-0444-7.CrossRefPubMed

12.

Kempf T, Zarbock A, Vestweber D, Wollert KC. Anti-inflammatory mechanisms and therapeutic opportunities in myocardial infarct healing. J Mol Med (Berl). 2012;90(4):361–9. https://doi.org/10.1007/s00109-011-0847-y.CrossRefPubMed

13.••

Heckmann MB, Reinhardt F, Finke D, Katus HA, Haberkorn U, Leuschner F, et al. Relationship between cardiac fibroblast activation protein activity by positron emission tomography and cardiovascular disease. Circ Cardiovasc Imaging. 2020;13(9):e010628. https://doi.org/10.1161/CIRCIMAGING.120.010628. This is an important paper demonstrating the correlation between cardiovascular diseases and FAPI uptake.CrossRefPubMedPubMedCentral

14.•

Lyu Z, Han W, Zhao H, Jiao Y, Xu P, Wang Y, et al. A clinical study on relationship between visualization of cardiac fibroblast activation protein activity by Al¹⁸F-NOTA-FAPI-04 positron emission tomography and cardiovascular disease. Front Cardiovasc Med. 2022;9:921724. https://doi.org/10.3389/fcvm.2022.921724. In this paper, further evidence are reported for a correlation between FAPI uptake and cardiovascular diseases.CrossRefPubMedPubMedCentral

15.

Varasteh Z, Mohanta S, Robu S, Braeuer M, Li Y, Omidvari N, et al. Molecular imaging of fibroblast activity after myocardial infarction using a ⁶⁸Ga-labeled fibroblast activation protein inhibitor, FAPI-04. J Nucl Med. 2019;60(12):1743–9. https://doi.org/10.2967/jnumed.119.226993.CrossRefPubMedPubMedCentral

16.

Langer LBN, Hess A, Korkmaz Z, Tillmanns J, Reffert LM, Bankstahl JP, et al. Molecular imaging of fibroblast activation protein after myocardial infarction using the novel radiotracer [⁶⁸Ga]MHLL1. Theranostics. 2021;11(16):7755–66. https://doi.org/10.7150/thno.51419.CrossRefPubMedPubMedCentral

17.••

Xie B, Wang J, Xi XY, Guo X, Chen BX, Li L, et al. Fibroblast activation protein imaging in reperfused ST-elevation myocardial infarction: comparison with cardiac magnetic resonance imaging. Eur J Nucl Med Mol Imaging. 2022;49(8):2786–97. https://doi.org/10.1007/s00259-021-05674-9. This is a very important paper, highlighting the correlation between post-infarction scar and FAPI uptake, which is related to reparative processes exceeding the extent of myocardial scar.CrossRefPubMed

18.••

Diekmann J, Koenig T, Zwadlo C, Derlin T, Neuser J, Thackeray JT, et al. Molecular imaging identifies fibroblast activation beyond the infarct region after acute myocardial infarction. J Am Coll Cardiol. 2021;77(14):1835–7. https://doi.org/10.1016/j.jacc.2021.02.019. Also in this paper, there is evidence that the area affected by reparative processes after myocardial infarction exceeds that of myocardial scar.CrossRefPubMed

19.

Notohamiprodjo S, Nekolla SG, Robu S, Villagran Asiares A, Kupatt C, Ibrahim T, et al. Imaging of cardiac fibroblast activation in a patient after acute myocardial infarction using ⁶⁸Ga-FAPI-04. J Nucl Cardiol. 2022;29(5):2254–61. https://doi.org/10.1007/s12350-021-02603-z.CrossRefPubMed

20.•

Kessler L, Kupusovic J, Ferdinandus J, Hirmas N, Umutlu L, Zarrad F, et al. Visualization of fibroblast activation after myocardial infarction using 68Ga-FAPI PET. Clin Nucl Med. 2021;46(10):807–13. https://doi.org/10.1097/RLU.0000000000003745. In this paper, a correlation between markers of cardiac injury and FAPI uptake is shown.CrossRefPubMed

21.

Qiao P, Wang Y, Zhu K, Zheng D, Song Y, Jiang D, et al. Noninvasive monitoring of reparative fibrosis after myocardial infarction in rats using ⁶⁸Ga-FAPI-04 PET/CT. Mol Pharm. 2022;19(11):4171–8. https://doi.org/10.1021/acs.molpharmaceut.2c00551.CrossRefPubMed

22.

Caobelli F, Nappi C. A spotlight on fibroblast-activated protein inhibitor (FAPi) cardiovascular imaging. Clin Transl Imaging. 2023. https://doi.org/10.1007/s40336-023-00548-6.CrossRef

23.

Wang G, Yang Q, Wu S, Xu X, Li X, Liang S, et al. Molecular imaging of fibroblast activity in pressure overload heart failure using [⁶⁸ Ga]Ga-FAPI-04 PET/CT. Eur J Nucl Med Mol Imaging. 2023;50(2):465–74. https://doi.org/10.1007/s00259-022-05984-6.CrossRefPubMed

24.

Song W, Zhang X, He S, Gai Y, Qin C, Hu F, et al. ⁶⁸Ga-FAPI PET visualize heart failure: from mechanism to clinic. Eur J Nucl Med Mol Imaging. 2023;50(2):475–85. https://doi.org/10.1007/s00259-022-05994-4.CrossRefPubMed

25.

Wang L, Zhang Z, Zhao Z, Yan C, Fang W. ⁶⁸Ga-FAPI right heart uptake in a patient with idiopathic pulmonary arterial hypertension. J Nucl Cardiol. 2022;29(3):1475–7. https://doi.org/10.1007/s12350-020-02407-7.CrossRefPubMed

26.

Xing H-Q, Gong J-N, Chen B-X, Guo X-J, Yang Y-H, Huo L, et al. Comparison of 68Ga-FAPI imaging and cardiac magnetic resonance in detection of myocardial fibrosis in a patient with chronic thromboembolic pulmonary hypertension. J Nucl Cardiol. 2022;29(5):2728–30. https://doi.org/10.1007/s12350-020-02517-2.CrossRefPubMed

27.

Chen BX, Xing HQ, Gong JN, Guo XJ, Xi XY, Yang YH, et al. Imaging of cardiac fibroblast activation in patients with chronic thromboembolic pulmonary hypertension. Eur J Nucl Med Mol Imaging. 2022;49(4):1211–22. https://doi.org/10.1007/s00259-021-05577-9.CrossRefPubMed

28.

Gu Y, Han K, Zhang Z, Zhao Z, Yan C, Wang L, et al. ⁶⁸Ga-FAPI PET/CT for molecular assessment of fibroblast activation in right heart in pulmonary arterial hypertension: a single-center, pilot study. J Nucl Cardiol. 2023;30(2):495–503. https://doi.org/10.1007/s12350-022-02952-3.CrossRefPubMed

29.•

Niu N, Huo L, Zhang S, Liu Y, Li X. Immune checkpoint inhibitor-associated cardiotoxicity detected by 68Ga-DOTATATE PET/CT and 68Ga-FAPI PET/CT. Eur Heart J Cardiovasc Imaging. 2022;23(3):e123. https://doi.org/10.1093/ehjci/jeab189. This paper highlights the potential role of FAPI to predict inflammatory cardiac alterations in patients under therapy with immune checkpoint inhibitors.CrossRefPubMed

30.

Totzeck M, Siebermair J, Rassaf T, Rischpler C. Cardiac fibroblast activation detected by positron emission tomography/computed tomography as a possible sign of cardiotoxicity. Eur Heart J. 2020;41(9):1060. https://doi.org/10.1093/eurheartj/ehz736.CrossRefPubMed

31.

Wei Y, Sun Y, Liu J, Zhang G, Qin X, Xu S, et al. Early detection of radiation-induced myocardial damage by [¹⁸F]AlF-NOTA-FAPI-04 PET/CT imaging. Eur J Nucl Med Mol Imaging. 2023;50(2):453–64. https://doi.org/10.1007/s00259-022-05962-y.CrossRefPubMed

32.

Wang L, Wang Y, Wang J, Xiao M, Xi XY, Chen BX, et al. Myocardial activity at ¹⁸F-FAPI PET/CT and risk for sudden cardiac death in hypertrophic cardiomyopathy. Radiology. 2023;306(2):e221052. https://doi.org/10.1148/radiol.221052.CrossRefPubMed

33.

Lin K, Chen X, Xue Q, Yao S, Miao W. Diffuse uptake of [⁶⁸Ga]Ga-FAPI in the left heart in a patient with hypertensive heart disease by PET/CT. J Nucl Cardiol. 2022;29(6):3596–8. https://doi.org/10.1007/s12350-021-02646-2.CrossRefPubMed

34.

Siebermair J, Kessler L, Kupusovic J, Rassaf T, Rischpler C. Cardiac fibroblast activation detected by ⁶⁸Gallium-FAPI-46 positron emission tomography-magnetic resonance imaging as a sign of chronic activity in cardiac sarcoidosis. Eur Heart J Case Rep. 2022;6(1):ytac005. https://doi.org/10.1093/ehjcr/ytac005.CrossRefPubMedPubMedCentral

35.

Guo W, Chen H. ⁶⁸Ga FAPI PET/MRI in cardiac amyloidosis. Radiology. 2022;303(1):51. https://doi.org/10.1148/radiol.211951.CrossRefPubMed

36.

Wang X, Guo Y, Gao Y, Ren C, Huang Z, Liu B, et al. Feasibility of ⁶⁸Ga-labeled fibroblast activation protein inhibitor PET/CT in light-chain cardiac amyloidosis. JACC Cardiovasc Imaging. 2022;15(11):1960–70. https://doi.org/10.1016/j.jcmg.2022.06.004.CrossRefPubMed

37.

Treutlein C, Distler JHW, Tascilar K, Fakhouri SC, Györfi AH, Atzinger A, et al. Assessment of myocardial fibrosis in patients with systemic sclerosis using [⁶⁸Ga]Ga-FAPI-04-PET-CT. Eur J Nucl Med Mol Imaging. 2023;50(6):1629–35. https://doi.org/10.1007/s00259-022-06081-4.CrossRefPubMed

38.

Si J, Zhang X, Chen N, Sun F, Du P, Li Z, et al. Case report: Multimodal imaging guides the management of an eosinophilic leukemia patient with eosinophilic myocarditis and intracardiac thrombus. Front Cardiovasc Med. 2022;9:903323. https://doi.org/10.3389/fcvm.2022.903323.CrossRefPubMedPubMedCentral

39.

Finke D, Heckmann MB, Herpel E, Katus HA, Haberkorn U, Leuschner F, et al. Early detection of checkpoint inhibitor-associated myocarditis using ⁶⁸Ga-FAPI PET/CT. Front Cardiovasc Med. 2021;8:614997. https://doi.org/10.3389/fcvm.2021.614997.CrossRefPubMedPubMedCentral

40.

Tillmanns J, Hoffmann D, Habbaba Y, Schmitto JD, Sedding D, Fraccarollo D, et al. Fibroblast activation protein alpha expression identifies activated fibroblasts after myocardial infarction. J Mol Cell Cardiol. 2015;87:194–203. https://doi.org/10.1016/j.yjmcc.2015.08.016.CrossRefPubMed

41.••

Zhang M, Quan W, Zhu T, Feng S, Huang X, Meng H, et al. [⁶⁸Ga]Ga-DOTA-FAPI-04 PET/MR in patients with acute myocardial infarction: potential role of predicting left ventricular remodeling. Eur J Nucl Med Mol Imaging. 2023;50(3):839–48. https://doi.org/10.1007/s00259-022-06015-0. A potential predictive role for FAPI imaging is here depicted, in regard to the prediction of ventricular remodelling.CrossRefPubMed

42.

Shi X, Lin X, Huo L, Li X. Cardiac fibroblast activation in dilated cardiomyopathy detected by positron emission tomography. J Nucl Cardiol. 2022;29(2):881–4. https://doi.org/10.1007/s12350-020-02315-w.CrossRefPubMed

43.

Zhang X, Song W, Qin C, Lan X. Different displays of ¹³N-NH₃ myocardial perfusion and cardiac ⁶⁸Ga-FAPI PET in immune checkpoint inhibitor-associated myocarditis-induced heart failure. Eur J Nucl Med Mol Imaging. 2023;50(3):964–5. https://doi.org/10.1007/s00259-022-06018-x.CrossRefPubMed

44.

Weber BN, Stevens E, Perez-Chada LM, Brown JM, Divakaran S, Bay C, et al. Impaired coronary vasodilator reserve and adverse prognosis in patients with systemic inflammatory disorders. JACC Cardiovasc Imaging. 2021;14(11):2212–20. https://doi.org/10.1016/j.jcmg.2020.12.031.CrossRefPubMedPubMedCentral

45.

Thackeray JT, Bengel FM. Molecular imaging of myocardial inflammation with positron emission tomography post-ischemia: a determinant of subsequent remodeling or recovery. JACC Cardiovasc Imaging. 2018;11(9):1340–55. https://doi.org/10.1016/j.jcmg.2018.05.026.CrossRefPubMed

46.

Caobelli F, Taqueti VR. Molecular imaging of myocardial inflammation: more evidence toward a causative role in cardiovascular disease. Curr Radiopharm. 2021;14(3):171–2. https://doi.org/10.2174/187447101403210715152013.CrossRefPubMed

47.

Horckmans M, Ring L, Duchene J, Santovito D, Schloss MJ, Drechsler M, et al. Neutrophils orchestrate post-myocardial infarction healing by polarizing macrophages towards a reparative phenotype. Eur Heart J. 2017;38(3):187–97. https://doi.org/10.1093/eurheartj/ehw002.CrossRefPubMed

48.

Wu E, Ortiz JT, Tejedor P, Lee DC, Bucciarelli-Ducci C, Kansal P, et al. Infarct size by contrast enhanced cardiac magnetic resonance is a stronger predictor of outcomes than left ventricular ejection fraction or end-systolic volume index: prospective cohort study. Heart. 2008;94(6):730–6. https://doi.org/10.1136/hrt.2007.122622.CrossRefPubMed

49.

Fu X, Khalil H, Kanisicak O, Boyer JG, Vagnozzi RJ, Maliken BD, et al. Specialized fibroblast differentiated states underlie scar formation in the infarcted mouse heart. J Clin Invest. 2018;128(5):2127–43. https://doi.org/10.1172/JCI98215.CrossRefPubMedPubMedCentral

Title: 68Ga-FAPi: Pathways and Diagnosis in Cardiac Imaging
Authors: Cristina Elena Popescu
Paola Ferro
Irene Gotuzzo
Irene Burger
Axel Rominger
Federico Caobelli
Publication date: 26-09-2023
Publisher: Springer US
Keywords: Positron Emission Tomography
Myocardial Infarction
Heart Failure
Published in: Current Cardiovascular Imaging Reports / Issue 11/2023
Print ISSN: 1941-9066
Electronic ISSN: 1941-9074
DOI: https://doi.org/10.1007/s12410-023-09583-3

2024 ASCO Annual Meeting

Springer Medicine

⁶⁸Ga-FAPi: Pathways and Diagnosis in Cardiac Imaging

Abstract

Purpose of Review

Recent Findings

Summary

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Purpose of Review

Recent Findings

Summary

Please log in to get access to this content